去纤苷适用人群及注意事项

Applicable groups for defibrotide: It is suitable for the treatment of adults and children with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT).

Clinical studies of defibrotide did not include sufficient numbers of subjects aged 65 and older to determine whether they responded differently than younger subjects. Other reported clinical experience has not identified differences in response between older and younger patients. Defibrotide may enhance the pharmacodynamic activity of antithrombotic/fibrinolytic agents such as heparin or alteplase. Concomitant use of defibrotide with antithrombotic or fibrinolytic agents due to increased risk of bleeding.

Precautions for defibrotide: 1. Defibrotide needs to be administered by injection, and defibrotide must be diluted before infusion. 2. Before administration of defibrotide, confirm that the patient has not experienced clinically significant bleeding and is hemodynamically stable on no more than one vasopressor. 3. Do not co-administer defibrotide and other intravenous drugs in the same intravenous line at the same time. 4. Hypersensitivity reaction: If a severe or life-threatening allergic reaction occurs, discontinue defibrotide, treat according to standard medical care, and monitor until signs and symptoms resolve.

Additionally, the pharmacodynamic activity of antithrombotic/fibrinolytic drugs such as heparin or alteplase may be enhanced. Concomitant use of defibrinoside with antithrombotic or fibrinolytic agents is contraindicated due to increased risk of bleeding. Bleeding: Defibrinoside increases plasmin activity in vitro, and sputum may increase the risk of bleeding after hematopoietic stem cell transplantation (HSCT) in patients with VOD. Do not initiate defibrotide in patients with active bleeding. Monitor patients for signs of bleeding. If a patient bleeds while taking defibrotide, discontinue defibrotide, treat the cause, and provide supportive care until bleeding has stopped.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: